August 14, 2020
In a proof-of-principle study, researchers at the Garvan Institute of Medical Research revealed a potential therapeutic approach for targeting estrogen receptor-positive (ER+) breast cancers resistant to current therapies. By combining current gold-standard treatments with a drug that restores the activity of p53, a cancer suppressor protein, the researchers found they […]